TargetBeta
TNFSF11
TNF superfamily member 11 · also TRANCE, RANKL, OPGL, ODF · CD molecules
3 programs in company-led studies act on TNFSF11, from 3 companies: 1 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Denosumabrule | Amgen | phase 4 | 795 running | – | NCIt |
| QL1206rule | Qilu Pharmaceutical | phase 3 | 51 running | – | ChEMBL |
| SHR-2017 | Jiangsu HengRui Medicine | phase 1 | 21 running | NGF | the company's pipeline |
Also acted on by the same programs
Conditions their studies are in
- Osteoporosis, 3 programs
- Neoplasm Metastasis, 2 programs
- Osteoporosis, Postmenopausal, 2 programs
- Breast Neoplasms, 1 program
- Giant Cell Tumor of Bone, 1 program
- Prostatic Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jan 2027QL1206 · Qilu Pharmaceutical · phase 3 · NCT07062978
- Jan 23, 2027Denosumab · Amgen · phase 4 · NCT06332014
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.